

PACIFIC EDGE CEO, DAVID DARLING, ANNOUNCES INTENTION TO RETIRE

Pacific Edge Limited (NZX: PEB) announces that CEO, David Darling, has advised the company's Board that he intends to retire from his role on 6 April 2022. Following this, David will continue to support the company in a consulting role.

The Board wishes to acknowledge the outstanding contribution David has made to Pacific Edge over the last 18 years and the passion and sustained energy he has brought to the role over that very long period of time. Chairman Chris Gallaher, said that Dave's expertise, persistence, and perseverance in the face of challenges over a long period of time have marked him as an outstanding CEO.

"During his tenure, Pacific Edge has grown from a research concept to a fully-fledged commercial entity well positioned to deliver the global growth potential of its technology. Dave has been the driving contributor to the development and execution of Pacific Edge's global strategy and lead the achievement of major commercial milestones in a highly competitive global market. He leaves the company in a strong position as we take the next steps in our commercial journey."

David Darling commented: "It has been a great privilege to have worked with such an outstanding team over the past 18 years, all of whom share the same passion for delivering better ways to diagnose and monitor cancer. Pacific Edge has a fantastic team, with proven performance and is well positioned to deliver the significant growth opportunities ahead of it. With the achievement of several major commercial milestones, the company is now in a new stage in its evolution. I believe that it is the right time for me to begin the process of succession to ensure a seamless transition over the next 12 months. I look forward to seeing the company's continued growth and development in the ensuing years."

The Board will commence a formal process to appoint the best and most capable person to fill this role and will update the market in due course.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.